GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Vanda Pharmaceuticals Inc. (VNDA) [hlAlert]

Rating:
Mkt Outperform
VNDA
up 188.91 %

Vanda Pharmaceuticals Inc. (VNDA) rated Mkt Outperform by JMP Securities

Posted on: Thursday,  Jan 17, 2013  8:25 AM ET by JMP Securities

JMP Securities rated Mkt Outperform Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) on 01/17/2013, when the stock price was $4.15.
Since then, Vanda Pharmaceuticals Inc. has gained 188.92% as of 01/27/2016's recent price of $11.99.
If you would have followed this JMP Securities's recommendation on VNDA, you would have gained 188.91% of your investment in 1105 days.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It's second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It's third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial.

MP Securities' equity research department provides institutional clients with comprehensive industry knowledge, unique insight and actionable information. JMP's senior research analysts are charged with developing proprietary investment themes, anticipating secular and cyclical changes and producing action-oriented reports. JMP follows companies in six industries that exhibit above-average long-term growth characteristics — Technology, Healthcare, Consumer, Real Estate, Financial Services and Business Services — and produces specialized equity research that enables investors to understand and invest in complicated growth stocks profitably.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/17/2013 8:25 AM Buy
None
4.15
as of 12/13/2013
1 Week down  -0.09 %
1 Month down  -20.93 %
3 Months down  -11.42 %
1 YTD up  148.43 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy